PolyHeme is a synthetic blood substitute developed by Northfield Laboratories to address a genuine crisis in emergency medicine: a shortage of safe donor blood, the risks of blood-borne pathogens, and the logistical challenges of blood typing under pressure. Unlike conventional blood, PolyHeme requires no refrigeration, carries no blood type antigens, and can be stored at room temperature, qualities that make it ideal for pre-hospital trauma care. In 2004, the FDA authorized a pivotal Phase III clinical trial enrolling 720 hemorrhagic shock victims under the Emergency Research Waiver (ERW), a 1966 provision allowing incapacitated patients to be enrolled in trials without their consent when no alternative exists.

​

The Polyneme trials began in 2003 and officially stopped recruiting patients in March 2006. The central ethical problem was not that patients were enrolled without consent in the field; the ERW explicitly permits this in true emergencies. The problem was that patients who received PolyHeme in the ambulance continued to receive it after arriving at the hospital, where standard blood transfusions were readily available. The waiver was never intended to justify withholding proven care once a patient reaches a fully equipped facility. Compounding this, Northfield Laboratories reportedly kept key study details from the Institutional Review Board and the FDA, and never held community consultation meetings a standard practice meant to give affected populations some voice in research conducted on them without individual consent.  

​

          The polyheme trials are also responsible for taking advantage of minority populations as their test subjects for these unethical trials. Thirteen of the 20 cities that were used for the study had minority populations greater than the national average. Cities like Maywood, illinos was targeted with a population that consists of 83% being black. Furthermore, participants in Detroit were 15 out of 16 minorities. These cities with large minority populations were targeted because they tend to have larger amounts of trauma cases. Northfield Laboratories disproportionately targeted minority populations, which made it easy for the researchers to conduct the trials since they would have many patient’s that face life-ending traumas.  This kind of targeting against minority groups continues to bring mistrust to medical researchers and Doctors.

​

The PolyHeme controversy sits within a long history of ethically troubled emergency research, like the Tuskegee Syphilis Study, which also targeted minority groups such as African Americans to advance medicine. The lesson of PolyHeme is not that emergency research exceptions are wrong, but that they are not blank checks. Procedural safeguards, transparent oversight, community engagement, and strict boundaries on what a consent waiver actually covers are the difference between medicine's highest calling and its most dangerous temptation.

​

References

 References

Apte, S. S. (2008). Blood substitutes- the polyheme trials. McGill Journal of Medicine : MJM, 11(1), 59. https://pmc.ncbi.nlm.nih.gov/articles/PMC2322929/

​

Blood Product Trial Had Disproportionate Amount of Minority Subjects - KFF Health News. (2026). KFF Health News. https://kffhealthnews.org/morning-breakout/dr00049555/

​

Chen, J.-Y., Scerbo, M., & Kramer, G. (2009). A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers. Clinics, 64(8). https://doi.org/10.1590/s1807-59322009000800016

​

McKenna, M. (2006). PolyHeme and the Ethics of Informed Consent. Annals of Emergency Medicine, 48(5), 563–566. https://doi.org/10.1016/j.annemergmed.2006.09.008

​

Potter, M. (2026). UCSD experiments with PolyHeme blood transfusions of comatose patients - south of I-8. San Diego Reader. https://www.sandiegoreader.com/news/2005/jul/28/bad-blood/

​

The. (2021, February 3). SocialEMpact. SocialEMpact. https://www.socialempact.com/viewpoints/bipocvax

​

(n.d.). Finance.senate.gov. https://www.finance.senate.gov/imo/media/doc/prg031306attach%20.pdf